(Q45994535)

English

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy.

scientific article published on 10 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

1 reference

based on heuristic

inferred from title

Giorgina Specchia

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

author name string

Guido Finazzi

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Alessandro M Vannucchi

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Vincenzo Martinelli

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Marco Ruggeri

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Francesco Nobile

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Enrico Maria Pogliani

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Odoardo Maria Olimpieri

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Giuseppe Fioritoni

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Caterina Musolino

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Daniela Cilloni

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Piera Sivera

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Giovanni Barosi

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Maria Chiara Finazzi

14

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Silvia Di Tollo

15

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Tim Demuth

16

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Tiziano Barbui

17

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

Alessandro Rambaldi

18

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

language of work or name

0 references

publication date

10 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

161

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

688-694

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of microtubules

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

How I treat patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F).

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Janus kinase 2: an epigenetic 'writer' that activates leukemogenic genes.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Polycythemia vera-associated pruritus and its management

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

New designs for the selection of treatments to be tested in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells.

1 reference

https://api.crossref.org/works/10.1111%2FBJH.12332

21 January 2018

Identifiers

10.1111/BJH.12332

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/23573950

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45994535&oldid=1560214314"